Dr. Dixon on Systemic Advances in Breast Cancer

J. Michael Dixon, MBChB, MD, Professor of Surgery and Consultant Surgeon of the University of Edinburgh; and Clinical Director of the Edinburgh Breast Unit at the Western General Hospital in Edinburgh, Scotland, describes all of the recent advances in breast cancer systemic therapy.

Dixon explains that in the hormonal systemic therapy there has been an advance in the treatment of postmenopausal women using aromatase inhibitors.

Chemotherapy and targeted agents have advanced considerably with the increased use of taxane drugs, anthracyclines, and anti-HER2 drugs such lapatinib and pertuzumab.